Who
Mitchel Sayare
Director
Company insider
Files Form 4 as: Director, Altimmune; Chairman of the Board, Immunogen.
In numbers
- Trades disclosed
- 146
- Buys
- 3
- Sells
- 18
- Bought
- $172K
- Sold
- $4.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 31 Jan 2006
- Last trade
- 1 May 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 26 Sep 2024filed 30 Sep 2024 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,900 at $0.00 | filing |
| 28 Sep 2023filed 29 Sep 2023 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,100 at $0.00 | filing |
| 29 Sep 2022filed 30 Sep 2022 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 23 Sep 2021filed 24 Sep 2021 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,100 at $0.00 | filing |
| 24 Sep 2020filed 16 Oct 2020 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,275 at $0.00 | filing |
| 24 Sep 2020filed 16 Oct 2020 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | —25,275 at $0.00 | filing |
| 24 Sep 2020filed 28 Sep 2020 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 25 Jun 2020filed 29 Jun 2020 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,275 at $0.00 | filing |
| 2 Jan 2019filed 4 Jan 2019 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Apr 2018filed 6 Apr 2018 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 29 Dec 2017filed 3 Jan 2018 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $9,9455,100 at $1.95 | filing |
| 13 Oct 2017filed 17 Oct 2017 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 22 Nov 2016filed 23 Nov 2016 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $30K20,000 at $1.52 | filing |
| 22 Nov 2016filed 23 Nov 2016 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $32K20,000 at $1.60 | filing |
| 22 Nov 2016filed 23 Nov 2016 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $160K60,000 at $2.67 | filing |
| 22 Nov 2016filed 23 Nov 2016 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $139K52,139 at $2.67 | filing |
| 22 Nov 2016filed 23 Nov 2016 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $29K20,000 at $1.45 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Mitchel Sayare; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.